News
08-16-2012, 01:11 AM
Treatment with denosumab resulted in a greater reduction in skeletal-related events in patients with breast cancer that spread to the bones compared with zoledronic acid, while also maintaining health-related quality of life, according to the results of a phase III study published in Clinical Cancer Research, a journal of the American Association for Cancer Research...
More... (http://www.medicalnewstoday.com/releases/249029.php)
More... (http://www.medicalnewstoday.com/releases/249029.php)